Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion criteria which must be verified at the end of first 18-months treatment (Visit 9)~* Having completed the previous 18-month treatment period of the EPAAC trial - NCT00152464~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 30 Months
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- LCTZ-LCTZ (Type: EXPERIMENTAL): Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
- LCTZ-PLC (Type: PLACEBO_COMPARATOR): Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
- PLC-PLC (Type: PLACEBO_COMPARATOR): Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)

Based on this trial design, predict the completion outcome and termination type (if applicable).